DOCSLIB.ORG

CTSA Program Meeting Welcome Session 111920.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
CTSA Program Meeting Welcome Session 111920.Pdf 2020 Fall Virtual CTSA Program Meeting Christopher P. Austin, M.D. Director, NCATS Welcome Session November 19, 2020 Congressional efforts to respond to the COVID-19 pandemic Four supplemental funding bills, including CARES Act Title Law Overview NIH Impact Coronavirus Aid, PL 116-136 Total: $2.3 Trillion (est.) FY 2020 Relief, and (3/27/20) Funds available until 9/30/24 to prevent, Economic Provides one-time payments to families, loans prepare for, and respond to coronavirus, Security (CARES) to businesses, emergency spending for federal domestically or internationally: Act agencies, aid to states and local governments, an expanded social safety net for the jobless, NHLBI: $103,400,000 and a cash infusion for the nation's hospitals. NIAID: $706,000,000 (includes $156,000,000 for facilities) NIBIB: $ 60,000,000 NLM: $ 10,000,000 NCATS: $ 36,000,000 OD: $ 30,000,000 (Common Fund) House and Senate have been unable to agree on a fifth Supplemental https://ncats.nih.gov/covid19-translational-approach NCATS OpenData Portal https://opendata.ncats.nih.gov/covid19/ Run as many screens and make our data against as many COVID against all immediately available targets as NCATS can… approved drugs… to the world The National COVID-19 Cohort Collaborative (N3C) • Making available vast amounts of clinical EHR data for speeding COVID-19 research and improving patient care • Centralized, secure data enclave that provides access to medical record data from people diagnosed with COVID-19 across the US • Harnesses resources of Clinical and Translational Sciences Awards (CTSA) Program hubs and Center for Data to Health (CD2H) https://ncats.nih.gov/n3c NCATS Convalescent Plasma RCTs Multisite trials run through CTSA TIN and hubs • NYU/Einstein CONTAIN Trial (NCT04364737) . Begun in April during peak of NYC caseload, target enrollment n=300 . Expanded in August to additional sites and target enrollment to n=1000 . Current active sites: 16 . Current total enrollment (as of November 11): 437 • Vanderbilt PassItOnII Trial (Passive Immunity Trial Of Nation II for COVID-19) (NCT04362176) . Also begun in April, during peak of Nashville caseload . Also expanded in August to include additional sites and target enrollment to n=1000 . Current active sites: 11 . Current total enrollment (as of November 11): 163 Funded by NCATS CARES Supplemental and Operation Warp Speed ACTIV-1 Immunomodulators Trial NCATS CTSA Trial Innovation Network/Hubs + CRO Launched October 16, 2020 Randomized, placebo-controlled master protocol evaluating multiple therapeutic agents for the treatment of moderately or severely ill patients infected with SARS-Cov-2 associated cytokine storm Evaluate each agent with respect to speed of recovery, mortality, illness severity, and hospital resource utilization. Each agent will be evaluated as add-on therapy to remdesivir (provided for all participants) plus the standard of care in use at local clinics, including convalescent plasma and dexamethasone in accordance with national guidelines. Patient Population: Hospitalized adults (≥18 years old) with COVID-19, including patients both in and out of the ICU STUDY AGENTS OUTCOME MEASURES • Infliximab (Remicade): anti-TNFα mAb Primary Endpoint Elevated TNF-α levels in severe COVID-19 • Time to Recovery by Day 29 • Abatacept (Orencia): CTLA-4-Ig fusion protein Key Secondary Endpoints Binds to Ag presenting cells limiting T-cell activation • Clinical Status on day 15 & Day 29 defined • Cenicriviroc (CVC): SM CCR2/CCR5 antagonist by COVID 8-point ordinal scale • 14-Day and 28-Day mortality Decreases activity of infiltrating macrophages 7 Departing Steering Committee Members 2018 - 2020 Barry Coller, M.D. Phil Kern, M.D. William Powderly, M.D. Rockefeller University University of Kentucky Washington University in St. Louis UL1 Member UL1 Member UL1 Member SC Co-Chair Welcome, New Steering Committee Members! 2021 - 2023 Don McClain, M.D. David McPherson, M.D. Muredach Reilly, M.D. Wake Forest University University of Texas Health Columbia University UL1 Member Science Center at Houston UL1 Member UL1 Member CTSA Program Steering Committee Co-Chair Appointments John Buse, M.D. Laura James, M.D. University of North Carolina, Chapel Hill University of Arkansas UL1 Member UL1 Member 2021 SC Co-Chair 2021 SC Co-Chair Designate 2022 SC Co-Chair CTSA Program Steering Committee Highlights Barry Coller, M.D. November 19, 2020 CTSA Program Steering Committee & Journal of Clinical and Translational Science COVID-19 Special Edition • Virtual visits Synergistically combined: • Interacting with the FDA: IND and EUA • Prioritizing studies unrelated to the emergency • Modifying laboratory testing via Home Brew during the emergency • Pharmacy: procurement, compounding, formulation • Risk: benefit analyses related to re-opening studies • Biorepositories and risks to research personnel • N3C and role of informatics • Protecting research personnel • Community engagement • Health disparities • Prioritizing studies of COVID-19 • IRB procedures, AAHRPP, OHRP • Informed consent This Photo by Unknown Author is licensed under CC BY-NC 13 Key takeaways from yesterday’s CTSA Program Steering Committee meeting CTSA Program Highlights Michael G. Kurilla, MD-PhD November 19, 2020 FY20 CTSA Program Overview • CTSA Program • New Hubs • New PIs • PI Accomplishments • Diversity and Re-Entry Support • Miscellaneous • Trans-NIH & Trans-Agency Activities • Addressing COVID-19 • New DCI Staff FY20 CTSA Program Hubs 18 New CTSA Program PIs (per Notices of Award 10/1/2019 - 10/28/2020) Megan H. Bair-Merritt, MD, John M. Arthur, MD, PhD* MSCE* Alexander G. Bassuk, MD, PhD Elisabet Borsheim, University of Arkansas for Boston University Medical University of Iowa PhD* Medical Sciences Campus KL2 University of Arkansas for KL2 UL1 Medical Sciences KL2 Ginny Bumgardner, MD, PhD* Mario Castro, MD, MPH Richard T. D’Aquila, MD The Ohio State University Michelle A. Chui, PharmD, PhD* University of Kansas Medical Northwestern University TL1 University of Wisconsin-Madison Center TL1 at Chicago UL1 UL1 Michael Demetriou, MD, PhD* Brownsyne Tucker Edmonds, Leonard E. Egede, MD, MS Patrick A. Flume, MD* University of California at Irvine MD, MPH, MS Medical College of Medical University of South KL2 Indiana University-Purdue Wisconsin Carolina University at Indianapolis KL2 UL1 KL2 Carolyn J. Greene, PhD* Claudia Lucchinetti, MD Julie Lumeng, MD* Susanna McColley, MD University of Arkansas for Mayo Clinic Rochester University of Michigan Northwestern University at Medical Sciences UL1 at Ann Arbor Chicago KL2 UL1 TL1 *Multiple Principal Investigators 19 New CTSA Program PIs (per Notices of Award 10/1/2019 - 10/28/2020) Duane A. Mitchell, MD, PhD Sharon M. Moe, MD* Ingrid E. Nygaard, MD, MS* Ruth O’Hara, PhD University of Florida Indiana University University of Utah Stanford University UL1 UL1 KL2 UL1 Nicholas J. Shaheen, MD, Shane A. Phillips PT, PhD, FAHA Richard Saitz, MD* Sarah J. Schlesinger, MD MPH* University of Illinois at Chicago Boston University The Rockefeller University University of North Carolina KL2 Medical Campus KL2 Chapel Hill UL1 UL1 Louise Walter, MD† Leena Sharma, MD Lauren Trepanier, DVM, PhD* Michael W. Varner, MD* University of California, Northwestern University at University of Wisconsin- University of Utah San Francisco Chicago Madison KL2 KL2 KL2 TL1 * Multiple Principal Investigators † Contact PI for Bauer (1 year) 20 NIH welcomes two new Institute Directors from CTSA hubs Lindsey A. Criswell, M.D., M.P.H., D.Sc. will direct the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Currently Vice Chancellor of Research at the University of California San Francisco (UCSF) • Former Co-PI UCSF Michael F. Chiang, M.D. will direct the National Eye Institute (NEI) • Currently Knowles Professor of Ophthalmology & Medical Informatics and Clinical Epidemiology at Oregon Health & Science University (OHSU) • Mentor for KL2 and TL1 participants at OHSU 21 Dr. Marcella Nunez-Smith named as one of three co-chairs of COVID-19 Transition Advisory Board “Everyone is affected by this pandemic, yet the burden is disproportionate. We know communities of color are grieving at high rates and are facing substantial economic impact. The transition advisory board is setting a course for everyone in our country to experience recovery.” – Dr. Marcella Nunez-Smith • Yale University Associate Professor of Internal Medicine, Public Health, and Management • Associate Dean for Health Equity Research at the Yale School of Medicine • Deputy Director of the Yale Center for Clinical Investigation (CTSA) • Founding Director of the Equity Research and Innovation Center (ERIC) Photo credit: Robert A Lisak • Director of the Center for Research Engagement (CRE) Katy B. Kozhimannil, PhD, MPA 2020 Heinz Award in Public Policy recipient for her work on rising maternal mortality rates in the rural U.S. and especially among women of color Her research has found that pregnant women in rural areas are 9% more likely to die from complications than those in more populated areas. Her work on how doulas could reduce maternal complications and racial inequities helped drive policy change in Minnesota: In 2013, the state passed legislation for Medicaid coverage of doula care. • Health policy researcher at the University of Minnesota • Community Engagement Team at UMN CTSA Hub • Part of the Mayo Maternal Mortality Admin Supplement (lead PI: Regan Theiler) “Acute Teleobstetrics services for management of maternal health emergencies.” 22 Congratulations
Load more

Recommended publications
  • THE IMMUNE SYSTEM Blood Cells Cells of the Immune System
    THE IMMUNE SYSTEM Blood Cells Cells of the Immune System White Blood Cells • Phagocytes - Neutrophils - Macrophages • Lymphocytes Phagocytes • Produced throughout life by the bone marrow. • Scavengers – remove dead cells and microorganisms. Neutrophils • 60% of WBCs • ‘Patrol tissues’ as they squeeze out of the capillaries. • Large numbers are released during infections • Short lived – die after digesting bacteria • Dead neutrophils make up a large proportion of puss. Macrophages • Larger than neutrophils. • Found in the organs, not the blood. • Made in bone marrow as monocytes, called macrophages once they reach organs. • Long lived • Initiate immune responses as they display antigens from the pathogens to the lymphocytes. Macrophages Phagocytosis Phagocytosis • If cells are under attack they release histamine. • Histamine plus chemicals from pathogens mean neutrophils are attracted to the site of attack. • Pathogens are attached to antibodies and neutrophils have antibody receptors. • Enodcytosis of neutrophil membrane phagocytic vacuole. • Lysosomes attach to phagocytic vacuole pathogen digested by proteases Lymphocytes • Produce antibodies • B-cells mature in bone marrow then concentrate in lymph nodes and spleen • T-cells mature in thymus • B and T cells mature then circulate in the blood and lymph • Circulation ensures they come into contact with pathogens and each other B -Lymphocytes • There are c.10 million different B- lymphocytes, each of which make a different antibody. • The huge variety is caused by genes coding for abs changing slightly during development. • There are a small group of clones of each type of B-lymphocyte B -Lymphocytes • At the clone stage antibodies do not leave the B- cells. • The abs are embedded in the plasma membrane of the cell and are called antibody receptors.
    [Show full text]
  • The Relationship Between Maternal Postpartum Psychological State and Breast Milk Secretory Immunoglobulin a Level
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Tsukuba Repository The Relationship Between Maternal Postpartum Psychological State and Breast Milk Secretory Immunoglobulin A Level 著者 Kawano Atsuko, Emori Yoko journal or Journal of the American Psychiatric Nurses publication title Association volume 21 number 1 page range 23-30 year 2015-01 権利 Authors URL http://hdl.handle.net/2241/00124572 doi: 10.1177/1078390314566882 The relationship between maternal postpartum psychological state and breast milk secretory immunoglobulin A level. Kawano A, Emori Y. J Am Psychiatr Nurses Assoc. 2015 Jan-Feb;21(1):23-30. doi: 10.1177/1078390314566882. Epub 2015 Jan 14. PMID:25589451 Abstract BACKGROUND: Maternal psychological state may influence the passive transfer of immune factors (e.g., immunoglobulin) via the mother’s breast milk. OBJECTIVE: The aim of this study was to determine whether a correlation exists between mothers’ postpartum psychological state and their breast milk secretory immunoglobulin A (SIgA) levels. STUDY DESIGN: Eighty-one mothers who delivered at an urban general hospital were included in our analysis. Two weeks after delivery, we measured their breast milk SIgA levels and simultaneously documented their psychological state using the Profile of Mood States (POMS), General Health Questionnaire (GHQ), and State-Trait Anxiety Inventory (STAI) scales. RESULTS: Breast milk SIgA levels were negatively correlated with negative POMS states (tension-anxiety, depression-dejection, anger-hostility, fatigue, and confusion). A negative correlation was also observed between SIgA levels and GHQ mental health (r = −.625, P = .000), and a similar negative correlation was observed with STAI trait and state anxieties.
    [Show full text]
  • Current Trends in Research on Human Milk Exchange for Infant Feeding
    Current trends in research on human milk exchange for infant feeding By: Aunchalee E. L. Palmquist, Maryanne T. Perrin, Diana Cassar-Uhl, Karleen D. Gribble, Angela B. Bond, and Tanya Cassidy Palmquist AEL, Perrin MT, Cassar-Uhl D, Gribble KD, Bond AB, Cassidy T. Current Trends in Research on Human Milk Exchange for Infant Feeding. Journal of Human Lactation. 2019;35(3):453-477. doi:10.1177/0890334419850820 Made available courtesy of SAGE publications: https://doi.org/10.1177/0890334419850820 ***© 2019 The Authors. Reprinted with permission. No further reproduction is authorized without written permission from SAGE. This version of the document is not the version of record. *** Abstract: Breastfeeding is critical for the healthy growth and development of infants. A diverse range of infant-feeding methods are used around the world today. Many methods involve feeding infants with expressed human milk obtained through human milk exchange. Human milk exchange includes human milk banking, human milk sharing, and markets in which human milk may be purchased or sold by individuals or commercial entities. In this review, we examine peer- reviewed scholarly literature pertaining to human milk exchange in the social sciences and basic human milk sciences. We also examine current position and policy statements for human milk sharing. Our review highlights areas in need of future research. This review is a valuable resource for healthcare professionals and others who provide evidence-based care to families about infant feeding. Keywords: human milk | human milk expression | infant-feeding patterns | lactation | milk banking | breastfeeding Article: Key Messages • Breastfeeding is critical for the healthy growth and development of infants, but it is not always possible or desired.
    [Show full text]
  • Greenbook Chapter 1
    Chapter 1: Immunity and how vaccines work December 2018 1 Immunity and how vaccines work vaccines work Introduction Immunity and how Immunity is the ability of the human body to protect itself from infectious disease. The defence mechanisms of the body are complex and include innate (non-specific, non-adaptive) mechanisms and acquired (specific, adaptive) systems. Innate or non-specific immunity is present from birth and includes physical barriers (e.g. intact skin and mucous membranes), chemical barriers (e.g. gastric acid, digestive enzymes and bacteriostatic fatty acids of the skin), phagocytic cells and the complement system. Acquired immunity is generally specific to a single organism or to a group of closely related organisms. There are two basic mechanisms for acquiring immunity – active and passive. Active immunity Active immunity is protection that is produced by an individual’s own immune system and is usually long-lasting. Such immunity generally involves cellular responses, serum antibodies or a combination acting against one or more antigens on the infecting organism. Active immunity can be acquired by natural disease or by vaccination. Vaccines generally provide immunity similar to that provided by the natural infection, but without the risk from the disease or its complications. Active immunity can be divided into antibody- mediated and cell-mediated components. Antibody-mediated immunity Antibody-mediated responses are produced by B lymphocytes (or B cells), and their direct descendants, known as plasma cells. When a B cell encounters an antigen that it recognises, the B cell is stimulated to proliferate and produce large numbers of lymphocytes secreting an antibody to this antigen.
    [Show full text]
  • I M M U N O L O G Y Core Notes
    II MM MM UU NN OO LL OO GG YY CCOORREE NNOOTTEESS MEDICAL IMMUNOLOGY 544 FALL 2011 Dr. George A. Gutman SCHOOL OF MEDICINE UNIVERSITY OF CALIFORNIA, IRVINE (Copyright) 2011 Regents of the University of California TABLE OF CONTENTS CHAPTER 1 INTRODUCTION...................................................................................... 3 CHAPTER 2 ANTIGEN/ANTIBODY INTERACTIONS ..............................................9 CHAPTER 3 ANTIBODY STRUCTURE I..................................................................17 CHAPTER 4 ANTIBODY STRUCTURE II.................................................................23 CHAPTER 5 COMPLEMENT...................................................................................... 33 CHAPTER 6 ANTIBODY GENETICS, ISOTYPES, ALLOTYPES, IDIOTYPES.....45 CHAPTER 7 CELLULAR BASIS OF ANTIBODY DIVERSITY: CLONAL SELECTION..................................................................53 CHAPTER 8 GENETIC BASIS OF ANTIBODY DIVERSITY...................................61 CHAPTER 9 IMMUNOGLOBULIN BIOSYNTHESIS ...............................................69 CHAPTER 10 BLOOD GROUPS: ABO AND Rh .........................................................77 CHAPTER 11 CELL-MEDIATED IMMUNITY AND MHC ........................................83 CHAPTER 12 CELL INTERACTIONS IN CELL MEDIATED IMMUNITY ..............91 CHAPTER 13 T-CELL/B-CELL COOPERATION IN HUMORAL IMMUNITY......105 CHAPTER 14 CELL SURFACE MARKERS OF T-CELLS, B-CELLS AND MACROPHAGES...............................................................111
    [Show full text]
  • Vaccines Why Use Passive Immunity?
    Vaccines n Active vs Passive Immunization n Active is longer acting and makes memory and effector cells n Passive is shorter acting, no memory and no effector cells n Both can be obtained through natural processes: n Getting antibodies from mother n Directly getting the disease n Or by unnatural processes n Being given pre-formed antibodies (gamma globulin shot) n Altered (attenuated) vaccines, toxoids n Immunity elicited in one animal can be transferred to another animal by injecting the recipient animal with serum from the immune animal n Passive immunization= pre-formed antibodies given from one individual to another (across placenta, gamma globulin injection) Why use passive immunity? n Deficiency in synthesis of Ig because of congenital or acquired defects n When a susceptible person is likely to be exposed to disease n When time does not permit adequate protection through active immunization n When a disease is already present and Ig may help to ameliorate or help to suppress the effects of toxin (tetanus, diphtheria or botulism) n Passive Immunity- n Natural maternal Ab & Immune globulin & Antitoxin n Active Immunity- n Natural Infection n Vaccines (attenuated & inactivated organisms & purified microbial proteins, cloned microbial antigens & toxoids) 1 n Tetanus- horse serum (horses do NOT get tetanus and can be injected with tetanus toxin) n Horse produces antibodies to toxin and when injected into person they act to neutralize toxin to prevent binding (serum sickness to horse albumin possible) n People can be given a toxoid (altered
    [Show full text]
  • 1. Introduction to Immunology Professor Charles Bangham ([email protected])
    MCD Immunology Alexandra Burke-Smith 1. Introduction to Immunology Professor Charles Bangham ([email protected]) 1. Explain the importance of immunology for human health. The immune system What happens when it goes wrong? persistent or fatal infections allergy autoimmune disease transplant rejection What is it for? To identify and eliminate harmful “non-self” microorganisms and harmful substances such as toxins, by distinguishing ‘self’ from ‘non-self’ proteins or by identifying ‘danger’ signals (e.g. from inflammation) The immune system has to strike a balance between clearing the pathogen and causing accidental damage to the host (immunopathology). Basic Principles The innate immune system works rapidly (within minutes) and has broad specificity The adaptive immune system takes longer (days) and has exisite specificity Generation Times and Evolution Bacteria- minutes Viruses- hours Host- years The pathogen replicates and hence evolves millions of times faster than the host, therefore the host relies on a flexible and rapid immune response Out most polymorphic (variable) genes, such as HLA and KIR, are those that control the immune system, and these have been selected for by infectious diseases 2. Outline the basic principles of immune responses and the timescales in which they occur. IFN: Interferon (innate immunity) NK: Natural Killer cells (innate immunity) CTL: Cytotoxic T lymphocytes (acquired immunity) 1 MCD Immunology Alexandra Burke-Smith Innate Immunity Acquired immunity Depends of pre-formed cells and molecules Depends on clonal selection, i.e. growth of T/B cells, release of antibodies selected for antigen specifity Fast (starts in mins/hrs) Slow (starts in days) Limited specifity- pathogen associated, i.e.
    [Show full text]
  • Lecture-2.Pdf
    DEPARTMENT OF BIOTECHNOLOGY FACULTY OFENGINEERING & TECHNOLOGY LT.1: IMMUNITY & ITS TYPES Content Outline 1. What is immunity? 2. Innate immunity & Passive immunity 3. Adaptive/Acquired immunity 4. Cells of adaptive immunity 5. Characteristic of innate and adaptive immunity 6. Immunity at glance 7. References & Further reading What is immunity? •The Latin term immunis, meaning “exempt,” is the source of the English word immunity, meaning the state of protectionf rom infectious disease. •Immunity is the capability of multi-cellular organisms to resist harmful microorganisms from entering their cells. •Immunity involves both specific and nonspecific components. •The nonspecific components act as barriers or eliminators of a wide range of pathogens irrespective of their antigenic make-up. Types of immunity •Innate immunity •Adaptive Immunity ( Acquired Immunity) Acquired immunity is further divided into two category •Naturally acquired immunity ( Active & passive) •Artificially acquired immunity ( Active & Passive) Innate immunity •Innate Immunity: Innate immunity refers to nonspecific defense mechanisms that come into play immediately or within hours of an antigen's appearance in the body. These mechanisms include physical barriers such as skin, chemicals in the blood, and immune system cells that attack foreign cells in the body. •Most components of innate immunity are present before the onset of infection and constitute a set of disease-resistance mechanisms that are not specific to a particular pathogen but that include cellular and molecular components that recognize classes of molecules peculiar to frequently encountered pathogens. Innate immunity can be seen to comprise four types of defensive barriers: anatomic, physiologic, phagocytic, and inflammatory Summary of non specific host response Adaptive/ Acquired immunity •Adaptive immunity is an immunity that occurs after exposure to an antigen either from a pathogen or a vaccination.
    [Show full text]
  • Saskatchewan Immunization Manual Chapter 13 – Principles of Immunology April 2012
    Saskatchewan Immunization Manual Chapter 13 – Principles of Immunology April 2012 1.0 THE IMMUNE SYSTEM...................................................................................1 1.1 INTRODUCTION......................................................................................................................... 1 1.2 CELLS OF THE IMMUNE SYSTEM ................................................................................................... 1 1.3 LYMPHATIC SYSTEM................................................................................................................... 2 1.4 TYPES OF IMMUNITY .................................................................................................................. 2 1.5 ACTIVE IMMUNITY..................................................................................................................... 4 1.6 INNATE IMMUNITY ‐ “FIRST” IMMUNE DEFENSE ............................................................................. 5 TABLE 1: INNATE IMMUNITY CHARACTERISTICS .................................................................................... 5 1.7 ADAPTIVE IMMUNITY ‐ “SECOND” IMMUNE DEFENCE ...................................................................... 6 1.8 ADAPTIVE IMMUNITY ‐ CELL MEDIATED IMMUNITY (CMI)................................................................ 6 1.9 ADAPTIVE IMMUNITY ‐ HUMORAL IMMUNITY ................................................................................. 7 1.10 ANTIBODIES ............................................................................................................................
    [Show full text]
  • BREASTFEEDING Connections
    BREASTFEEDING Connections May 2021 This newsletter is intended to be viewed online in order to access the hyperlinks. In addition to receiving it via email, you can access the electronic version on our website. www.Michigan.gov/Wic Inside This Issue Special Foods and Local Herbs used to Enhance Milk Peer Counselor Q & A 2-3 Production in Ghana: Rate of Use and Belief of Efficacy New Breast Pumps 3 Reviewed by Jennifer Walker, CLC at Detroit Health Department Coffective Corner 4 AAP on Breastfeeding 4 Not making enough milk to feed their babies is one of the most common worries of Peer Spotlight 5 breastfeeding mothers. In many areas of Ghana, mothers have been using foods Newborn Wgt Tool 5 and herbs to help with lactogogue/galactogogues (prescription drugs, foods and Training Options 6-7 herbs) that help increase milk production. A study was conducted in 2018, in two DEI Update 7 areas of Ghana, among 402 lactating mothers. Most of the mothers started using a Breastmilk & Covid 8 galactogogue within the first 24 hours postpartum. Twenty of the women were selected for a focus group and answered questions for specific food and herbs that were used for lactation. It was found that supplemental foods and herbs were taken because of traditions handed down from grandmothers and female elders in the This newsletter is prepared family. Mothers would often not seek advice from health care providers or for Michigan WIC Staff to breastfeeding professionals until after they had already started to use a help them support galactogogue. Although there is no limited scientific research that supplements breastfeeding families.
    [Show full text]
  • Greenbook Chapter 1 Immunity and How Vaccines Work
    Chapter 1: Immunity and how vaccines work January 2021 1 Immunity and how vaccines work vaccines work Introduction Immunity and how Immunity is the ability of the human body to protect itself from infectious disease. The defence mechanisms of the body are complex and include innate (non-specific, non- adaptive) mechanisms and acquired (specific, adaptive) systems. Innate or non-specific immunity is present from birth and includes physical barriers (e.g. intact skin and mucous membranes), chemical barriers (e.g. gastric acid, digestive enzymes and bacteriostatic fatty acids of the skin), phagocytic cells and the complement system. Acquired immunity is generally specific to a single organism or to a group of closely related organisms. There are two basic mechanisms for acquiring immunity – active and passive. Active immunity Active immunity is protection that is produced by an individual’s own immune system and is usually long-lasting. Such immunity generally involves cellular responses, serum antibodies or a combination acting against one or more antigens on the infecting organism. Active immunity can be acquired by natural disease or by vaccination. Vaccines generally provide immunity similar to that provided by the natural infection, but without the risk from the disease or its complications. Active immunity can be divided into antibody- mediated and cell-mediated components. Antibody-mediated immunity Antibody-mediated responses are produced by B lymphocytes (or B cells), and their direct descendants, known as plasma cells. When a B cell encounters an antigen that it recognises, the B cell is stimulated to proliferate and produce large numbers of lymphocytes secreting an antibody to this antigen.
    [Show full text]
  • Breast Milk-Fed Infant of COVID-19 Pneumonia Mother: a Case Report
    Breast Milk-fed Infant of COVID-19 Pneumonia Mother: a Case Report Yuanyuan Yu The Fourth Aliated Hospital Zhejiang University School of Medicine https://orcid.org/0000-0003- 3106-7112 Jian Xu ( [email protected] ) The Fourth Aliated Hospital Zhejiang University School of Medicine https://orcid.org/0000-0002- 0307-3198 Youjiang Li The Fourth Aliated Hospital Zhejiang University School of Medicine Yingying Hu The Fourth Aliated Hospital Zhejiang University School of Medicine Bin Li The Fourth Aliated Hospital Zhejiang University School of Medicine Case Report Keywords: COVID-19, SARS-CoV-2, breastfeeding Posted Date: April 7th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-20792/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/11 Abstract In China, mothers with conrmed or suspected COVID-19 pneumonia are recommended to stop breastfeeding. However, the evidence to support this guidance is lacking. This report analyzes the case of a mother who persisted breastfeeding her baby when both were diagnosed with conrmed COVID-19 pneumonia. SARS-CoV-2 nucleic acid was not detected in the breast milk, and antibodies against SARS- CoV-2 were present in detected in the mother's serum and milk. There was no evidence of mother-to-child transmission of the virus through breastfeeding. This case report demonstrates that breastfeeding may even be useful for improving the recovery of the infant without exacerbating disease severity. Background In early December 2019, a new coronavirus named SARS-CoV–2 broke out in Wuhan, China, affecting the susceptible population and causing a highly infectious COVID–19 pneumonia (1).
    [Show full text]